Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | ($148.9M) | ($100.8M) | ($76.9M) | ($85.3M) | ($159.3M) | ($139.8M) | $14.0M | ($143.2M) | $1,148.0K | ($16.1M) | ($4,804.0K) | $50.7M | $145.0M | ($243.7M) | $129.2M | $402.0M | ($240.3M) | $585.8M | $579.4M | $620.5M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Incyte Corporation's last 12-month Operating Income is ($52.0M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Incyte Corporation's Operating Income growth was N/A. The average annual Operating Income growth rates for Incyte Corporation have been N/A over the past three years, N/A over the past five years.